The company is also excited to share the addition of key advisory positions, Jessica Kates (Rellevant Partners), Pamela Watkins (DuPont), and Rob Le Bras-Brown (HP Inc.).
Lieutenant General Thomas P. Bostick previously served as COO and president, Intrexon Bioengineering (NASDAQ: XON).
He serves as a senior advisor on biotechnology, infrastructure, sustainability, HR, and DEI.
Bostick serves on the boards of CSX (NASDAQ: CSX), and Perma-Fix (NASDAQ: PESI). He also serves on the board of HireVue, and Fidelity Investments' Equity and High-Income Fund board of Trustees.
He was the 53rd Chief of Engineers and Commanding General of the US Army Corps of Engineers.
Bostick serves on multiple non-profit boards. A member of the National Academy of Engineering, Bostick serves on several committees of the National Academy of Sciences focused on the environment and climate change.
He is a licensed professional engineer, a Forbes Contributor, and an Affiliated Scholar at Stanford University.
Bostick recently published his first book, Winning After Losing: Building Resilient Teams.
Allonnia is focused on a number of government related waste challenges including the treatment of PFAS contaminated sites and upcycling of rare earth elements.
Bostick's expertise mix is synergistic with Allonnia's priorities as they progress through continuing to build their federal and industrial strategy for development and deployment.
In addition to strengthening the board, Allonnia adds three industry veterans as advisors to strengthen day-to-day operations. The advisors bring both industry and functional expertise spanning Finance, People and Marketing.
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer